- Home
- ICCM vs CANF Comparison
ICCM vs CANF Comparison
Compare ICCM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | CANF |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.7M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ICCM | CANF |
|---|---|---|
| Price | $1.63 | $2.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $50.00 |
| AVG Volume (30 Days) | 86.1K | ★ 211.9K |
| Earning Date | 05-27-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | $2,715,455.50 |
| Revenue Next Year | $75.66 | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.17 |
| 52 Week High | $9.54 | $10.40 |
Technical Indicators
Market Signals| Indicator | ICCM | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 22.40 | 33.50 |
| Support Level | $0.22 | $2.16 |
| Resistance Level | $2.50 | $2.39 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 4.71 | 24.00 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.